CA2784033A1 - A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection - Google Patents

A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection Download PDF

Info

Publication number
CA2784033A1
CA2784033A1 CA2784033A CA2784033A CA2784033A1 CA 2784033 A1 CA2784033 A1 CA 2784033A1 CA 2784033 A CA2784033 A CA 2784033A CA 2784033 A CA2784033 A CA 2784033A CA 2784033 A1 CA2784033 A1 CA 2784033A1
Authority
CA
Canada
Prior art keywords
antibody
patient
region
pcrv
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2784033A
Other languages
English (en)
French (fr)
Inventor
Geoffrey T. Yarranton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Humanigen Inc
Original Assignee
Kalobios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalobios Pharmaceuticals Inc filed Critical Kalobios Pharmaceuticals Inc
Publication of CA2784033A1 publication Critical patent/CA2784033A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2784033A 2009-12-22 2010-12-21 A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection Abandoned CA2784033A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28897709P 2009-12-22 2009-12-22
US61/288,977 2009-12-22
PCT/US2010/061636 WO2011087799A1 (en) 2009-12-22 2010-12-21 A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection

Publications (1)

Publication Number Publication Date
CA2784033A1 true CA2784033A1 (en) 2011-07-21

Family

ID=44224810

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2784033A Abandoned CA2784033A1 (en) 2009-12-22 2010-12-21 A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection

Country Status (5)

Country Link
US (1) US8642039B2 (https=)
EP (1) EP2515935A4 (https=)
JP (1) JP2013515079A (https=)
CA (1) CA2784033A1 (https=)
WO (1) WO2011087799A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8597689B2 (en) * 2006-10-25 2013-12-03 Revalesio Corporation Methods of wound care and treatment
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US20090263495A1 (en) * 2007-10-25 2009-10-22 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US20100310665A1 (en) * 2007-10-25 2010-12-09 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
BR112012028540A2 (pt) 2010-05-07 2016-07-26 Revalesio Corp composições e métodos para melhorar desempenho fisiológico e tempo de recuperação
JP2013533320A (ja) 2010-08-12 2013-08-22 レバレジオ コーポレイション タウオパチーを治療するための組成物および方法
BR112013031485B1 (pt) 2011-06-10 2022-06-14 Medimmune, Llc Anticorpo monoclonal isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, usos e método in vitro para bloqueio ou prevenção da ligação de p. aeruginosa a células epiteliais
BR112014011028B1 (pt) 2011-11-07 2021-03-02 Medimmune, Llc anticorpo biespecífico, composição, e, uso da composição
TWI719938B (zh) * 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
EP3288974B1 (en) 2015-05-01 2020-11-04 Inhibrx, Inc. Type iii secretion system targeting molecules
CN113811544A (zh) 2019-03-13 2021-12-17 免疫医疗有限责任公司 减少定殖患者中的金黄色葡萄球菌感染
CN118620074A (zh) * 2020-06-01 2024-09-10 北京三诺佳邑生物技术有限责任公司 特异性识别假单胞菌pcrv的抗体及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69930166T2 (de) * 1998-11-25 2006-12-14 MCW Research Foundation, Inc., Milwaukee Verfahren und zusammensetzungen für impfung mit dem pseudomonas aeruginosa v-antigen
EP2316419B1 (en) * 2004-05-17 2012-07-11 Gilead Sciences, Inc. Aerosolized fosfomycin/tobramycin combination for the treatment of bacterial respiratory infections
US20060228384A1 (en) * 2005-04-06 2006-10-12 Sequoia Sciences, Inc. Control of biofilm with a biofilm inhibitor
US8268347B1 (en) * 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
BRPI0817311A2 (pt) * 2007-09-25 2015-03-17 Novartis Ag Tratamento de doenças pulmonares com medicamentos em aerossol tais como a vancomicina
EP2220117A2 (en) * 2007-11-30 2010-08-25 Kalobios Pharmaceuticals, Inc. Antibodies to the pcrv antigen of pseudomonas aeruginosa
WO2010091189A1 (en) 2009-02-04 2010-08-12 Kalobios Pharmaceuticals, Inc. Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection

Also Published As

Publication number Publication date
EP2515935A4 (en) 2013-08-28
US20110165172A1 (en) 2011-07-07
WO2011087799A1 (en) 2011-07-21
JP2013515079A (ja) 2013-05-02
EP2515935A1 (en) 2012-10-31
US8642039B2 (en) 2014-02-04

Similar Documents

Publication Publication Date Title
US8642039B2 (en) Method of treating a staphylococcus infection in a patient having a low-level pathogenic Pseudomonas aeruginosa infection
AU2008333985B2 (en) Antibodies to the PcrV antigen of pseudomonas aeruginosa
TWI719938B (zh) 多重細菌感染之治療
US8653242B2 (en) Therapeutic antibodies against flagellated Pseudomonas aeruginosa
JP2011505381A5 (https=)
EP4032904A1 (en) Anti-alpha-hemolysin antibody and use thereof
JP2022163050A (ja) 院内肺炎を予防または治療する方法
US20100272736A1 (en) Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection
WO2024020236A2 (en) Monoclonal antibodies that interfere with iron uptake
US20240254219A1 (en) Novel wnt agonist antibodies and therapeutic uses thereof
CA3207447A1 (en) Antibodies that bind glucosaminidase and uses thereof
EA043404B1 (ru) Биспецифические антитела против плазменного калликреина и фактора xii

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20161221